Acute Myeloid Leukemia with FLT3 Mutation

Acute Myeloid Leukemia with FLT3 Mutation — Trials · CancerIndex

Clinical trials

Registered studies

15 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4
Recruiting: 3
Ph III recruiting: 0
Growth YoY: —
Industry share: 50%
Top sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (4)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06222580	SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation	recruiting	Phase 1	30	Uma BorateOTHER	1	May 14, 2026	clinicaltrials
NCT05024552	Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML	recruiting	Phase 1	22	H. Lee Moffitt Cancer Center and Research InstituteOTHER	1	Dec 5, 2025	clinicaltrials